Biomea Fusion, Inc. reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on oral small-molecule therapies for diabetes, obesity and related metabolic diseases. Its updates center on icovamenib, an investigational oral covalent menin inhibitor being evaluated in type 1 and type 2 diabetes, and BMF-650, an investigational oral GLP-1 receptor agonist candidate for obesity.
Recurring announcements include COVALENT trial results and study initiations, measures of beta-cell function, C-peptide, glycemic control and safety, scientific presentations at diabetes and metabolic-disease meetings, investor-conference activity, and periodic financial results with pipeline updates.
Biomea Fusion (BMEA) announced that its management team will participate in three upcoming healthcare investor conferences in London, Miami and New York.
The schedule includes Jefferies on November 19, 2026, Citi on December 2 and Piper Sandler on December 3. Jefferies and Piper Sandler will feature fireside chats, with live audio webcasts and subsequent replays available on Biomea's website. Management will hold one-on-one investor meetings at all three conferences.
Biomea Fusion (Nasdaq: BMEA) reported a narrower third-quarter net loss while advancing its clinical programs for diabetes and obesity. Net loss was $6.183 million, or $0.09 per share, versus $16.407 million, or $0.27 per share, a year earlier. Cash, cash equivalents and restricted cash totaled $26.772 million at September 30, 2026; the company projects runway into the second quarter of 2027.
COVALENT-211 enrollment is complete, while COVALENT-212 enrollment continues. Biomea expects Week 26 blood-sugar endpoint data in the first and second quarters of 2027, respectively. The OPAL combination study dosed its first patient, with topline data anticipated at the end of 2027. BMF-650 Phase I results showed Day 29 mean weight reductions of 1.5%–3.2% in outpatient cohorts versus 0.1% for pooled placebo. The confined cohort lost 6.1%, but confinement appeared to affect eating behavior, limiting comparison.
Biomea Fusion (BMEA) will present Phase 1 results for investigational BMF-650 at ObesityWeek 2026 on November 16, 2026.
BMF-650 is an oral small molecule GLP-1 receptor agonist. Thorsten A. Kirschberg, Ph.D., will present the first-in-human study results in Poster 828 from 2:30–3:30 p.m. ET. The conference runs November 14–17 at the Gaylord National Resort & Convention Center in National Harbor, Maryland. The poster will be available afterward in the Investors & Media section of the company’s website.
Biomea Fusion (Nasdaq: BMEA) announced Phase 1 results for BMF-650, an investigational oral GLP-1 receptor agonist, showing weight reduction over four weeks.
In overweight or obese, otherwise healthy adults, mean Day 29 weight reduction in Cohorts 1–4 ranged from 1.5% to 3.2%, versus 0.1% for pooled placebo. Among 40 active-dose participants across five multiple-dose cohorts, no severe or serious treatment-emergent adverse events, related dose modifications or related discontinuations occurred. Cohort 5 reached 400 mg once daily after one week at 200 mg; mean weight reduction was 6.1%, but its two placebo participants had similar reductions. Biomea believes confinement affected eating behavior and warrants separate interpretation of this cohort.
Further development requires longer-term toxicology studies. Biomea intends to continue that work while seeking a partnership that could include licensing for late-stage development and commercialization.
Biomea Fusion (Nasdaq: BMEA) will report results from its Phase I GLP-131 study of BMF-650 on October 13, 2026. BMF-650 is an investigational oral small-molecule drug designed to activate the GLP-1 receptor. Management will discuss the results on a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) that day. The webcast will be available through the company’s Investors and Media website section, with a replay following the event.
Biomea Fusion (BMEA) has terminated its proposed public offering of securities announced on September 22, 2026, citing market conditions.
Management determined that current market conditions are not conducive to completing an offering on terms viewed as in the best interests of stockholders. No securities were sold in connection with the proposed offering. The now-terminated offering had been planned under an effective Form S-3 shelf registration statement and a preliminary prospectus supplement filed on September 22, 2026.
Biomea Fusion (BMEA) has commenced an underwritten public offering of common stock and, for certain investors, pre-funded warrants to purchase common shares.
The company plans to grant the underwriter a 30-day option to buy up to an additional 15% of the total number of shares and pre-funded warrants. All securities in the proposed offering will be sold by Biomea, and completion, size and terms remain subject to market and other conditions. Konik Capital Partners, a division of T.R. Winston & Company, is acting as sole underwriter. The offering is being made under an effective shelf registration statement on Form S-3 filed August 5, 2025 and declared effective August 15, 2025.
Biomea Fusion (BMEA) will participate in two investor conferences in September 2026 in New York. Management will attend Citi's 2026 Biopharma Back to School Conference for one-on-one investor meetings on September 10, 2026. The company will also present at the H.C. Wainwright 28th Annual Global Investment Conference at 11:00 a.m. ET on September 15, 2026, and hold additional one-on-one meetings. An audio webcast and replay of the H.C. Wainwright presentation will be available on Biomea’s website under Investors & Media.
Biomea Fusion (Nasdaq: BMEA) announced completion of enrollment in COVALENT-211, a randomized, double-blind, placebo-controlled Phase II trial of icovamenib in insulin-deficient type 2 diabetes patients inadequately controlled on standard antihyperglycemic therapies. The study enrolled 64 participants across 18 sites, randomized 2:1 to icovamenib 100 mg once daily or placebo for 12 weeks, followed by a 40-week off-treatment period through Week 52. The primary endpoint is assessed at Week 26, with topline data expected in Q1 2027.
COVALENT-212, targeting T2D patients not at glycemic targets despite GLP-1–based therapy, continues enrolling and is expected to complete enrollment before year end, with 26-week primary endpoint data anticipated in Q2 2027. Both trials leverage Phase II COVALENT-111 data, where icovamenib showed durable, placebo-adjusted HbA1c reductions up to 1.5% and 1.8% at Week 52 and was generally well tolerated without treatment-related serious adverse events or discontinuations.
Biomea Fusion (Nasdaq: BMEA) reported dosing the first participant in a new arm of the OPAL study, a multi-arm open-label adaptive platform trial run with the University of Leicester and Leicester Diabetes Centre. The experimental arm tests Biomea’s investigational small molecule icovamenib (100 mg once daily for 12 weeks) combined with low-dose semaglutide (24 weeks) versus low-dose semaglutide alone in overweight or obese adults without type 2 diabetes.
This randomized, double-blind arm will enroll 64 participants, allocated 1:1. The study will assess whether adding icovamenib can enhance weight loss and will measure effects on physical function, body composition, muscle health, and metabolic outcomes, with the primary endpoint at Week 24. Preclinical data showed icovamenib improved semaglutide-driven weight loss, favoring fat loss while preserving lean mass and modulating GLP-1 expression and adipose metabolism.